COMP <GO>
BCRX vs RXRX // DIVIDEND YIELD & FCF PAYOUT SAFETY
BioCryst Pharmaceuticals Inc. (NASDAQ) VS. Recursion Pharmaceuticals Inc. (NASDAQ) • 15-METRIC TALLY: BCRX 5
— RXRX 1
■ METRIC PARITY
LAST: $8.24 (-2.66%) • MKT CAP: $2.11B
dividend-safety
0.00%
LAST: $3.83 (-4.96%) • MKT CAP: $2.29B
dividend-safety
0.00%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (BCRX VS. RXRX)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | BCRX | RXRX | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 5.00% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 85.00% | -35.00% | +120.00 | BCRX | /roic <GO> |
| EV/EBITDA & P/E Valuation | 6.1x | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 15.96% | -14.95% | +30.91 | BCRX | /fcf-yield <GO> |
| Operating Margin | — | -60.00% | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | -60.00% | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | 26.90% | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety ACTIVE | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | 1.59 | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | 4/9 | +2.00 | BCRX | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 48.8 | 47.8 | +1.00 | BCRX | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 1.00 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 7.7x | 32.0x | -24.30 | BCRX | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $2.11B | $2.29B | -$179.2M | RXRX | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | BCRX REV | RXRX REV | BCRX GROSS % | RXRX GROSS % | BCRX FCF | RXRX FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $954.8M | $74.7M | — | 5.0% | $347.4M | -$378.3M |
| FY 2024 | $7.1M | $58.8M | — | 23.1% | -$52.0M | -$372.9M |
| FY 2023 | $290.4M | $44.6M | — | — | -$95.1M | -$289.8M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
BCRX // BETA —
RXRX // BETA 1.00